INSMED INC Retained Earnings
INSMED INC (INSM) had Retained Earnings of -$5.81 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$5.81B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$5.80B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$5.64B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$5.31B.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$5.81B 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$5.80B 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$5.64B 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$5.31B 10-Q · filed 2025-10-30 |
| 2025-06-30 | -$4.94B 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$4.62B 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$4.36B 10-K · filed 2026-02-19 |
| 2024-09-30 | -$4.12B 10-Q · filed 2024-10-31 |
| 2024-06-30 | -$3.90B 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$3.60B 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$3.45B 10-K · filed 2025-02-20 |
| 2023-09-30 | -$3.26B 10-Q · filed 2023-10-26 |
| 2023-06-30 | -$3.10B 10-Q · filed 2023-08-03 |
| 2023-03-31 | -$2.86B 10-Q · filed 2023-05-04 |
| 2022-12-31 | -$2.70B 10-K · filed 2024-02-22 |
| 2022-09-30 | -$2.54B 10-Q · filed 2022-10-27 |
| 2022-06-30 | -$2.41B 10-Q · filed 2022-08-04 |
| 2022-03-31 | -$2.31B 10-Q · filed 2022-05-05 |
| 2021-12-31 | -$2.27B 10-K · filed 2023-02-23 |
| 2021-09-30 | -$2.15B 10-Q · filed 2021-10-28 |
| 2021-06-30 | -$2.04B 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$1.92B 10-Q · filed 2021-05-06 |
| 2020-12-31 | -$1.83B 10-K · filed 2022-02-17 |
| 2020-09-30 | -$1.73B 10-Q · filed 2020-10-29 |
| 2020-06-30 | -$1.66B 10-Q · filed 2020-08-06 |
| 2020-03-31 | -$1.60B 10-Q · filed 2020-04-30 |
| 2019-12-31 | -$1.54B 10-K · filed 2021-02-25 |
| 2019-09-30 | -$1.48B 10-Q · filed 2019-10-30 |
| 2019-06-30 | -$1.42B 10-Q · filed 2019-08-01 |
| 2019-03-31 | -$1.36B 10-Q · filed 2019-05-07 |
| 2018-12-31 | -$1.28B 10-K · filed 2020-02-25 |
| 2018-09-30 | -$1.19B 10-Q · filed 2018-10-30 |
| 2018-06-30 | -$1.10B 10-Q · filed 2018-08-02 |
| 2018-03-31 | -$1.03B 10-Q · filed 2018-05-02 |
| 2017-12-31 | -$957.88M 10-K · filed 2019-02-22 |
| 2017-09-30 | -$892.50M 10-Q · filed 2017-11-02 |
| 2017-06-30 | -$847.32M 10-Q · filed 2017-08-03 |
| 2017-03-31 | -$802.65M 10-Q · filed 2017-05-03 |
| 2016-12-31 | -$765.24M 10-K · filed 2018-02-23 |
| 2016-09-30 | -$696.83M 10-Q · filed 2016-11-03 |
| 2016-06-30 | -$659.07M 10-Q · filed 2016-08-04 |
| 2016-03-31 | -$622.50M 10-Q · filed 2016-05-05 |
| 2015-12-31 | -$588.96M 10-K · filed 2017-02-23 |
| 2015-09-30 | -$557.72M 10-Q · filed 2015-11-06 |
| 2015-06-30 | -$526.76M 10-Q · filed 2015-08-06 |
| 2015-03-31 | -$498.15M 10-Q · filed 2015-05-07 |
| 2014-12-31 | -$470.78M 10-K · filed 2016-02-25 |
| 2014-09-30 | -$453.13M 10-Q · filed 2014-11-06 |
| 2014-06-30 | -$429.14M 10-Q · filed 2014-08-06 |
| 2014-03-31 | -$405.92M 10-Q · filed 2014-05-08 |
| 2013-12-31 | -$391.62M 10-K · filed 2015-02-27 |
| 2013-09-30 | -$375.41M 10-Q · filed 2013-11-05 |
| 2013-06-30 | -$358.08M 10-Q · filed 2013-08-06 |
| 2013-03-31 | -$349.23M 10-Q · filed 2013-05-07 |
| 2012-12-31 | -$335.55M 10-K · filed 2014-03-06 |
| 2012-09-30 | -$320.10M 10-Q · filed 2012-11-07 |
| 2012-06-30 | -$310.71M 10-Q · filed 2012-08-07 |
| 2012-03-31 | -$301.02M 10-Q · filed 2012-05-08 |
| 2011-12-31 | -$294.17M 10-K · filed 2013-03-18 |
| 2011-09-30 | -$286.01M 10-Q · filed 2011-11-09 |
| 2011-06-30 | -$251.42M 10-Q/A · filed 2011-08-08 |
| 2010-12-31 | -$234.51M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |